Venn Life Sciences Holdings PLC New services from Innovenn

TIDMVENN

Venn Life Sciences Holdings PLC

20 May 2015

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Innovenn now offering microbiology & histology services from new state of the art labs

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, today announced that InnoVenn, the skin science division of Venn, has expanded its service offering with the addition of Microbiology and Histology services.

Innovenn offers clients in the cosmetic, personal care, medical device and pharmaceutical sectors tailor-made research programmes to develop skincare ingredients and products. The new services include the antimicrobial profiling of ingredients, investigation of pro and prebiotic effects on natural microflora and the quantitative microbiology of the skin. Innovenn's renowned team of experts carry out research using their leading human skin equivalent, Labskin, which allows for the direct testing of topical materials and formulations on a living skin surface.

The Company's Skin Histology laboratory provides services dedicated to cutaneous biology, including sample processing, imaging and evaluation. It is tightly integrated with the LabSkin in vitro skin model production and testing facility, enabling customers to conduct animal-free assessments of their ingredients and products for multiple parameters including irritation, penetration, UV damage, and antimicrobial activity. Innovenn has also recently expanded its workforce to deal with increasing international demand for their research and development services and the production of Labskin.

Commenting on the additional services Venn CEO, Tony Richardson stated: These new services demonstrate the capabilities of Labskin and how innovative, robust and precise the product is. We are looking forward to offering these services to our current and expanding list of international clients".

Enquiries:

 
 Venn Life Sciences Holdings                    www.vennlifesciences.com 
  Plc 
 Tony Richardson, Chief                             Tel: +353 154 99 341 
  Executive Officer 
 Orla McGuinness, Marketing                           Tel: +33 676931178 
  Manager 
 
 Zeus Capital (Nominated 
  Adviser and Broker) 
 Ross Andrews/Andrew Jones                            Tel: 0161 831 1512 
 Alex Davies                                          Tel: 020 7533 7727 
 
 Walbrook PR Ltd               Tel: 020 7933 8787 or venn@walbrookpr.com 
 Paul McManus                                         Mob: 07980 541 893 
 Lianne Cawthorne                                     Mob: 07584 391 303

About InnoVenn

InnoVenn (55.6% owned by Venn) is a market development accelerator dedicated to rapidly commercialising proven scientific breakthroughs in the form of products and technologies primarily in Skin Science. These include Labskin the breakthrough research grade human skin testing platform as well as the clinically proven Blemish Control Technology for the professional skincare market. For more information on Innovenn, visit www.innovenn.co.uk

About Venn Life Sciences Limited

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science. For more information, visit www.vennlifesciences.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRALLFFEEVIALIE

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024